Professor Andy Hall
Associate Dean of Translational Research

Introduction 

Associate Dean of Translational Research

Professor of Experimental Haematology

Roles and Responsibilities

  • Associate Dean for Translational Research
  • Director, Newcastle Biomedicine Biobank
  • Designated Individual for Human Tissue Act Research Licence for Newcastle University
  • Professor of Experimental Haematology
  • Honorary Consultant Haematologist, Newcastle upon Tyne NHS Foundation Trust
  • Pathology Lead, NCRI Confederation of Cancer Biobanks

Qualifications

MBBS
FRCP
PhD
FRCPath

Memberships

American Society of Hematology,
American Association for Cancer Research,
British Society of Haematology,
British Association of Cancer Research

External Roles

Member, NIHR Clinical Research Fellowship Panel
Chair, Scientific Advisory Panel, Bone Cancer Research Trust
Member,HTA stakeholder and Fees Group

 

Research Interests

Using intensive combination chemotherapy more than 80% of children with acute lymphoblastic leukaemia (ALL) achieve long-term remission. However, relapsed ALL remains the most frequent cause of death from malignancy under the age of 15. My main research focus has been the study of the biology of relapse in ALL with the aim of discovering the causes of chemoresistance and suggesting ways of improving long-term survival in relapsed disease.

Previous studies undertaken by the Molecular Pharmacology Group in Newcastle have indicated that cell line models are of limited value in predicting mechanisms of drug resistance in patients. Our research has shown this may be in part be due to the fact that the majority of lymphoid cell lines are mismatch repair defective but that this is uncommon in the clinical setting (Matheson et al, 2003). We have shown, for example, that point mutations in the glucocorticoid receptor are a common cause of steroid resistance in CCRF-CEM cells, a frequently used, mismatch repair defective, T-cell line, but do not underlie resistance in mismatch repair proficient preB697 cells (Schmidt/Irving et al, 2006) and are very uncommon in clinical samples (Irving et al 2005).

These findings have led us to alter our approach to the study of drug resistance in leukaemia to focus on the use of clinical material. We have pioneered the use of single nucleotide polymorphism microarrays to determine allelic imbalance in leukaemic cells and have demonstrated progressive loss of heterozygosity in matched samples taken at presentation and on relapse (Irving et al, 2005). Recently we have made a significant contribution to a study which has demonstrated that deletion of BACH2 may be involved in leukaemogeneis (Swaminathan, 2013)

Studies are underway to extend these observations in collaboration with colleagues both in the UK and abroad and to develop ways of exploiting progressive change which we have identified.

Working with the Quality Assurance Manager for the Newcastle Biomedicine Biobank I deliver regular teaching on the Human Tissue Act to research and clinical staff. In addition I teach MRes students about the ethical issues involved in the use of tissues for medical research as part of the bioethics module.